RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.
Kashmir Valley
Papillary thyroid cancer
RET/PTC rearrangement
TSH
Thyroid Cancer
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
04
10
2018
accepted:
12
11
2018
pubmed:
24
11
2018
medline:
14
1
2021
entrez:
24
11
2018
Statut:
ppublish
Résumé
Rearranged during transfection (RET) is a proto oncogene implicated in thyroid carcinogenesis of papillary type (PTC). The RET proto-oncogene in PTC is constitutively activated by fusion of its tyrosine kinase domain with the 5 ´region of another gene thereby generating chimeric products collectively named RET/PTCs. RET/PTC1 and RET/PTC3 are best characterized among all RET/PTC rearrangements. Kashmir valley has witnessed an alarming increase in thyroid cancer incidence in young women. Therefore, we investigated the occurrence of RET/PTC 1 & 3 rearrangements by semi quantitative and qPCR in thyroid cancer patients (n = 48) of Kashmiri population and interrelated results with various clinicopathological characteristics. We observed that all the RET/PTC rearrangements were confined to PTC cases (10/40). Presence of RET/PTC rearrangement significantly correlated with gender, elevated TSH levels and lymph node metastasis. Overall, our study advocates that RET/PTC3 rearrangement is a frequent event in the carcinogenesis of thyroid gland in Kashmiri population although a study with a larger sample size is needed to get a clear scenario.
Identifiants
pubmed: 30467698
doi: 10.1007/s12253-018-0540-3
pii: 10.1007/s12253-018-0540-3
doi:
Substances chimiques
MAS1 protein, human
0
Oncogene Proteins, Fusion
0
Proto-Oncogene Mas
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins c-ret
EC 2.7.10.1
RET protein, human
EC 2.7.10.1
ret-PTC fusion oncoproteins, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-513Subventions
Organisme : Department of Biotechnology, Ministry of Science and Technology, Govt. of India
ID : BT/PR4626/MED/30/702/2012 dated: 07.08.2013
Références
Jpn J Cancer Res. 1992 Jul;83(7):671-5
pubmed: 1381340
Endocr J. 2011;58(1):31-8
pubmed: 21173509
Mutagenesis. 2014 Mar;29(2):131-7
pubmed: 24442520
Nat Rev Endocrinol. 2016 Apr;12(4):192-202
pubmed: 26868437
J Clin Endocrinol Metab. 2015 Mar;100(3):788-93
pubmed: 25546157
Endocr Pathol. 2015 Dec;26(4):315-9
pubmed: 26260781
Endocr Pathol. 2002 Spring;13(1):3-16
pubmed: 12114746
J Clin Endocrinol Metab. 2000 Aug;85(8):2733-9
pubmed: 10946873
Oncogene. 2010 Apr 15;29(15):2272-80
pubmed: 20101222
Biochimie. 1997 Oct;79(9-10):619-23
pubmed: 9466701
Oncogene. 2000 Nov 20;19(49):5590-7
pubmed: 11114739
Int J Cancer. 1999 Jan 5;80(1):32-8
pubmed: 9935226
Eur J Endocrinol. 2011 Oct;165(4):499-507
pubmed: 21750045
Eur J Endocrinol. 2001 Nov;145(5):599-604
pubmed: 11720878
Int J Surg Pathol. 2000 Jul;8(3):185-189
pubmed: 11493988
Eur J Endocrinol. 2003 May;148(5):505-13
pubmed: 12720532
Oncotarget. 2016 Mar 29;7(13):16716-30
pubmed: 26918339
Br J Cancer. 1998 Mar;77(6):903-6
pubmed: 9528832
J Clin Endocrinol Metab. 1998 May;83(5):1629-32
pubmed: 9589668
Adv Anat Pathol. 2001 Nov;8(6):345-54
pubmed: 11707626
Laryngoscope. 1997 Jan;107(1):95-100
pubmed: 9001272
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
J Intern Med. 2003 Jun;253(6):627-33
pubmed: 12755958
J Clin Endocrinol Metab. 1999 Nov;84(11):4232-8
pubmed: 10566678
J Cancer Epidemiol. 2013;2013:965212
pubmed: 23737785
Am J Surg Pathol. 2006 Feb;30(2):216-22
pubmed: 16434896
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
Int J Endocrinol. 2017;2017:5308635
pubmed: 28555155
Tumour Biol. 2013 Feb;34(1):521-9
pubmed: 23150177
Cancer. 1994 Jan 1;73(1):176-80
pubmed: 8275421
Cancer Res. 2008 Sep 1;68(17):7176-82
pubmed: 18757433
Thyroid. 1999 Dec;9(12):1237-43
pubmed: 10646664